2025 SABCS Abstracts to Action: From Data to Decisions in HR+ Breast Cancer Care

Program Description

As the therapeutic landscape for breast cancer rapidly evolves, oncology pharmacists must stay at the forefront of clinical updates to ensure the safe, effective, and operationally sound integration of novel agents into practice. This panel discussion will provide a comprehensive analysis of select practice-impacting abstracts from the 2025 San Antonio Breast Cancer Symposium, with a focus on HR+/HER2-negative breast cancer. Experts will evaluate the integration of novel pharmacotherapeutic approaches, including oral selective estrogen receptor degraders, AKT inhibitors, and antibody-drug conjugates. By addressing critical operational and payer-related challenges, including prior authorizations and infusion capacity, this program highlights the oncology pharmacist’s vital role in translating high-level clinical evidence into optimized, individualized patient care and in navigating complex treatment sequencing and updated guideline recommendations.

Target audience: Oncology Pharmacists
Type of activity: Application
Release date: March 6, 2026
Expiration date: March 6, 2027
Learner level: Advanced
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore recent clinical updates on novel and emerging pharmacotherapeutic approaches for the management of HR+/HER2-negative breast cancer presented at the 2025 San Antonio Breast Cancer Symposium (SABCS)
• Examine how emerging clinical evidence in HR+/HER2-negative breast cancer impacts oncology pharmacy practice, including both clinical decision-making and operational workflows
• Apply clinical insights alongside operational considerations and payer-related factors to guide the use of novel pharmacotherapeutic strategies in individualized care of patients with HR+/HER2-negative breast cancer

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-26-019-H01-P. The activity is available for CE credit through March 6, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Rose DiMarco, PharmD, BCPS, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: BMS, IO Biotech, Lilly, Jazz, Sanofi, Urogen

Speakers Bureau: Lilly

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Allison Butts, PharmD, BCOP

Irvin Molina, PharmD, BCOP, BCPS, CSP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms